Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash & Equivalents (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Cash & Equivalents for 6 consecutive years, with $38.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 4089.72% to $38.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $38.3 million, a 4089.72% increase, with the full-year FY2024 number at $56.5 million, up 516.36% from a year prior.
  • Cash & Equivalents was $38.3 million for Q3 2025 at Inhibikase Therapeutics, down from $77.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $77.7 million in Q2 2025 to a low of $913420.0 in Q3 2024.
  • A 5-year average of $26.6 million and a median of $14.9 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 601525.64% in 2021, then plummeted 94.09% in 2023.
  • Inhibikase Therapeutics' Cash & Equivalents stood at $40.8 million in 2021, then crashed by 82.36% to $7.2 million in 2022, then increased by 27.5% to $9.2 million in 2023, then skyrocketed by 516.36% to $56.5 million in 2024, then crashed by 32.25% to $38.3 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Cash & Equivalents are $38.3 million (Q3 2025), $77.7 million (Q2 2025), and $73.4 million (Q1 2025).